Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
78 hedge funds and large institutions have $168M invested in Cascadian Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 5 closing their positions.
500% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 5
165% more capital invested
Capital invested by funds: $63.3M → $168M (+$105M)
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
37% more funds holding
Funds holding: 57 → 78 (+21)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$30.6M |
| 2 |
BG
Baupost Group
Boston,
Massachusetts
|
+$19.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$17.1M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.6M |
| 5 |
A
Abingworth
London,
United Kingdom
|
+$3.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$2.29M |
| 2 |
FO
FT Options
Chicago,
Illinois
|
-$145K |
| 3 |
First Eagle Investment Management
New York
|
-$108K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$97.7K |
| 5 |
EWM
Edge Wealth Management
New York
|
-$85K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Simplex Trading
Chicago,
Illinois
| – | +$130 | +31 | New |
|
CASC Hedge Fund Activity: Q1 2017 in Review
78 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q1 2017, worth a combined $168M — up 165% from $63.3M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CASC positions and 5 closed out — a net gain of 25 holders — while 25 added to existing stakes and 10 trimmed.
The largest buyer was NEA Management Company, adding an estimated $30.6M. The largest seller was Perceptive Advisors, cutting an estimated $2.29M.
- 78 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q1 2017, up from 57 in Q4 2016.
- Funds reported $168M of Cascadian Therapeutics, Inc. stock for Q1 2017, up 165% quarter-over-quarter.
- 30 funds opened new Cascadian Therapeutics, Inc. positions in Q1 2017 and 5 closed out, a net change of +25 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q1 2017 was NEA Management Company, an estimated $30.6M added.
- The largest Cascadian Therapeutics, Inc. seller in Q1 2017 was Perceptive Advisors, an estimated $2.29M sold.
Based on aggregated 13F filings for Q1 2017.